History of LHRH agonist and combination therapy in prostate cancer

Endocrine-Related Cancer

Volumn 3, Issue 3, 1996, Pages 243-278

  Labrie, F ^a   Belanger A ^a   Cusan, L ^a   Labrie, C ^a   Simard, J ^a   Luu The, V ^a   Diamond, P ^a   Gomez, J L ^a   Candas, B ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; CHLORMADINONE ACETATE; CYPROTERONE ACETATE; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; LUTRELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NAFARELIN; NILUTAMIDE;

ANIMAL MODEL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NONHUMAN; ORCHIECTOMY; ORGAN SIZE; PREOPERATIVE TREATMENT; PROSTATE CANCER; REVIEW; SEMINAL VESICLE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0029914066     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0030243     Document Type: Review

References (154)

1. 10] ethylamide on LH/hCG and PRL testicular receptor levels in the rat. Endocrinology 101 1890-1893.
2. Auclair C, Kelly PA, Labrie F, Coy DH & Schally AV 1977b Inhibition of testicular LH/hCG receptor level by treatment with a potent LHRH agonist of hCG. Biochemical and Biophysical Research Communications 76 855-862.
3. Baird BT, Horton R, Longcope C & Tait JF 1969 Steroid dynamics under steady-state conditions. Recent Progress in Hormone Research 26 611-664.
4. Barradell LB & Faulds D 1994 Cyproterone: a review of its pharmacology and therapeutic efficacy in prostatic cancer. Drugs and Aging 5 59-80.
5. Bartsch W, Knabbe M & Voigt KD 1983 Regulation and compartmentalization of androgens in rat prostate and muscle. Journal of Steroid Biochemistry 19 929-937.
6. Bélanger A, Auclair C, Séguin C, Kelly PA & Labrie F 1979 Down-regulation of testicular androgen biosynthesis and LH receptor levels by an LHRH agonist, role of prolactin. Molecular and Cellular Endocrinology 13 47-53.
7. Bélanger A, Cusan L, Auclair C, Séguin C, Caron S & Labrie F 1980a Effect of an LHRH agonist and hCG on testicular steroidogenesis in the adult rat. Biology of Reproduction 22 1094-1101.
8. 10]LHRH agonist, on serum steroid levels in normal adult men. Journal of Steroid Biochemistry 13 123-126.
9. Bélanger A, Brochu M & Cliche J 1986 Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. Journal of Clinical Endocrinology and Metabolism 62 812-815.
10. Bélanger B, Bélanger A, Labrie F, Dupont A, Cusan L & Monfette G 1989 Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. Journal of Steroid Biochemistry 32 695-698.
11. Bergquist C, Nillius SJ, Berg T, Skarin G & Wide L 1979a Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. Acta Endocrinologica 91 601-608.
12. Bergquist C, Nillius SJ & Wide L 1979b Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent. Lancet i 215-217.
13. Bhanalaph T, Varkarakis MJ & Murphy GP 1974 Current status of bilateral adrenalectomy in advanced prostatic carcinoma. Annals of Surgery 179 17-23.
14. Borgeat P, Labrie F, Côté J, Ruel F, Schally AV, Coy DH, Coy EJ & Yanaihara N 1974 Parallel stimulation of cyclic AMP accumulation and LH and FSH release by analogs of LHRH in vitro. Molecular and Cellular Endocrinology 1 7-20.
15. Bourne GA, Regiani S, Payne AH & Marshall JC 1980 Testicular GnRH receptors. Characterization and localization of interstitial tissue. Journal of Clinical Endocrinology and Metabolism 51 407-409.
16. Cassileth BB, Soloway MS, Vogelzang NJ, Schellhammer PS, Seidmon EJ, Hait HI & Kennealey GT 1989 Patient's choice of treatment in stage D prostate cancer. Urology 33 57-62.
17. Chen C, Poulin R & Labrie F 1996 Large Shionogi tumors lose their responsiveness to Flutamide treatment. Journal of Steroid Biochemistry and Molecular Biology (In Press).
18. Clayton RN 1982 Absence of gonadotropin-releasing hormone receptors in human gonadal tissue. Nature 299 56-59.
19. Cowley TH, Brownsey BG, Harper ME, Peeling WB & Griffiths K 1976 The effect of ACTH on plasma testosterone and androstenedione concentrations in patients with prostatic carcinoma. Acta Endocrinologica 81 310-320.
20. 10]LHRH ethylamide, a peptide with greatly enhanced LH- and FSH-releasing activity. Biochemical and Biophysical Research Communications 57 335-340.
21. Coy DH, Labrie F, Savary M, Coy EJ & Schally AV 1975 LH-releasing activity of potent LHRH analogs in vitro. Biochemical and Biophysical Research Communications 67 576-582.
22. Coy DH, Vilchez-Martinez JA, Coy EJ & Schally AV 1976 Analogs of luteinizing hormone-releasing hormone (LHRH) increased biological activity produced by amino acid substitutions in position 6. Journal of Medicinal Chemistry 19 423-425.
23. Crawford D, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein DA, Davis MA & Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine 321 419-424.
24. Cusan L, Auclair C, Bélanger A, Ferland L, Kelly PA, Séguin C & Labrie F 1979 Inhibitory effects of long-term treatment with an LHRH agonist on the pituitary-gonadal axis in male and female rats. Endocrinology 104 1369-1376.
25. Denis L, Carneiro de Moura JL, Bono A, Sylvester R, Wheeton R, Newling D & Pauno MD 1993 Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42 119-129.
26. Di Silverio F, Sciarra F & D'Eramo G 1990 Advanced prostatic cancer: clinical and hormonal response to Flutamide in patients pretreated with LHRH analogue and cyproterone acetate. European Urology 18 10-15.
27. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E & Motta M 1994 Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Research 54 4091-4095.
28. Drouin J & Labrie F 1976 Selective effect of androgens on LH and FSH release in anterior pituitary cells in culture. Endocrinology 98 1528-1534.
29. Drouin, J, Lagacé L & Labrie F 1976 Estradiol-induced increase of the LH responsiveness to LHRH in rat anterior pituitary cells in culture. Endocrinology 99 1477-1481.
30. El Etreby MF, Habenicht UF, Louton T, Nishino Y & Schroder HG 1987 Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle and adrenal glands of adult male rats. Prostate 11 361-374.
31. Elger W 1966 Die Rolle der setalen Androgen in der sexual Disserenzierung des Kanichens und ihre. (Partie I and II). Archives d'Anatomie Microscopique et de Morphologie 55 658-670.
32. Faure N, Labrie F, Lemay A, Bélanger A, Gourdeau Y, Laroche B & Robert G 1982 Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (GNRH) agonist in adult men. Fertility and Sterility 37 416-424.
33. Ferguson JD 1975 Limits and indications for adrenalectomy and hypophysectomy in the treatment of prostatic cancer. In Hormonal Therapy of Prostatic Cancer, pp 201-207. Eds U Bracci & F Di Silverio. Palermo: Cofese Edizioni.
34. Ferland L, Drouin J & Labrie F 1976 Role of sex steroids on LH and FSH secretion in the rat. In Hypothalamus and Endocrine Functions, pp 191-209. Eds F Labrie, J Meites & G Pelletier. New York: Plenum Press.
35. Fowler JE & Whitmore WF 1981 The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. Journal of Urology 126 372-375.
36. Fugino M, Kobayashi S, Obayashi M, Shinagawa S, Fukuda T, Nakayama R, Yamazaki I, White WF & Rippel RH 1972 Structure-activity relationships in the C-terminal part of luteinizing hormone-releasing hormone (LHRH). Biochemical and Biophysical Research Communications 49 863-869.
37. Furr BJA, Valcaccia B, Curry B, Woodburn JR, Chesterson G & Tucker H 1987 ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen. Journal of Endocrinology 113 R7-R9.
38. Geller J 1985 Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Seminars in Oncology 12 28-35.
39. Geller J 1991 Review of assessment of total androgen blockade as treatment of metastatic prostate cancer. Journal of Endocrinological Investigation 14 881-891.
40. Geller J, Albert J, Loza D, Geller S, Stoeltzing W & Vega DDL 1978 DHT concentrations in human prostate cancer tissue. Journal of Clinical Endocrinology and Metabolism 46 440-444.
41. Geller J, Albert JD, Nachtsheom DA & Loza DC 1984 Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. Journal of Urology 132 693-696.
42. Gittes RF 1991 Carcinoma of the prostate. New England Journal of Medicine 24 236-245.
43. Graf KJ, Kleinechke RI & Neumann F 1974 The stimulation of male duct derivatives in female guinea pigs with an antiandrogen cyproterone acetate. Journal of Reproduction and Fertility 39 311-317.
44. Griffiths K, Eaton CL & Davies P 1989 Prostatic cancer: aetiology and endocrinology. Hormone Research 32 38-43.
45. Griffiths K, Harper ME & Peeling WB 1995 Some aspects of the biology and endocrinology of prostate cancer. Scandinavian Journal of Clinical and Laboratory Investigation (Suppl) 221 23-31.
46. Harper ME, Pike A, Peeling WB & Griffiths K 1974 Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. Journal of Endocrinology 60 117-125.
47. Harris AL & Cantwell BMJ 1985 Side effects of endocrine therapies used to treat breast and prostate cancer. Clinical Oncology 4 511-533.
48. Harrison JH, Thorn G W & Jenkins D 1953 Total adrenalectomy for reactivated carcinoma of the prostate. New England Journal of Medicine 248 86-92.
49. Hierowski MT, Altamirano P, Redding TW & Schally AV 1983 The presence of LHRH-like receptors in Dunning R3327H prostate tumors. FEBS Letters 154 92-96.
50. Horton R 1978 Sex steroid production and secretion in the male. Andrologia 10 183-184.
51. Hsueh AJW, Dufau ML & Catt KJ 1976 Regulation of luteinizing hormone receptors in testicular interstitial cells by gonadotropin. Biochemical and Biophysical Research Communications 72 1145-1152.
52. Hsueh AJW, Dufau ML & Catt KJ 1977 Gonadotropin-induced regulation of luteinizing hormone receptors and desensitization of testicular 3′,5′-cyclic AMP and testosterone response. Proceedings of the National Academy of Sciences of the USA 74 592-595.
53. Huggins C & Hodges CV 1941 Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293-307.
54. Huggins C & Scott WW 1945 Bilateral adrenalectomy in prostatic cancer. Annals of Surgery 122 1031-1041.
55. Huggins C, Scott WW & Hodges CV 1941a Studies on prostatic cancer. III. The effects of fever, of desoxycorticosterone and estrogen on clinical patients with metastatic carcinoma of the prostate. Annual Meeting of the American Urological Association, pp 997-1006.
56. Huggins C, Stevens RE & Hodges CV 1941b Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Archives of Surgery 43 209-223.
57. Jacobi OH & Wenderoth UK 1982 Gonadotrophin-releasing hormone analogues for prostate cancer untoward side effects of high-dose regimens acquire a therapeutical dimension. European Urology 8 129-134.
58. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Silva FCd, Knonagel H & Venner P 1993 Orchiectomy and Anandron (Nilutamide) or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. Journal of Urology 149 77-83.
59. 6-LH-RH, in normal men. International Journal of Fertility 22 77-84.
60. Johnson ES 1977 Treatment of prostatic hyperplasia. US Patent No 4,005,194.
61. Jordan VC, Collin MM, Rowsby L & Prestwich G 1977 A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. Journal of Endocrinology 75 305-316.
62. Kelly S, Labrie F & Dupont A 1983 Loss of LH bioactivity in men treated with an LHRH agonist and an antiandrogen. Proceedings of the 65th Annual Meeting of the Endocrine Society, Abstract no. 81.
63. Krabbe S & Shakkebaek NE 1977 Gonadotropin-releasing hormone (LHRH) and human chorionic gonadotropin in the treatment of two boys with hypogonadotrophic hypogonadism. Acta Paediatrica Scandinavica 66 361-365.
64. Labrie F 1991 Intracrinology. Molecular and Cellular Endocrinology 78 C113-C118.
65. Labrie F 1993 Intracrinology: its impact on prostate cancer. Current Opinion in Urology 3 381-387.
66. Labrie F & Veilleux R 1986 A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. Prostate 8 293-300.
67. Labrie F, Auclair C, Cusan L, Kelly PA, Pelletier G & Ferland L 1978 Inhibitory effects of LHRH and its agonists on testicular gonadotropin receptors and spermatogenesis in the rat. International Journal of Andrology (Suppl) 2 303-318.
68. Labrie F, Bélanger A, Cusan L, Séguin C, Pelletier G, Kelly PA, Reeves JJ, Lefebvre FA, Lemay A & Ranaud JP 1980 Antifertility effects of LHRH agonists in the male. Journal of Andrology 1 209-228.
69. Labrie F, Dupont A, Bélanger A, Cusan L, Lacourcière Y, Monfette G, Laberge JG, Emond J, Fazekas ATA, Raynaud JP & Husson JM 1982 New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Journal of Clinical and Investigative Medicine 5 267-275.
70. Labrie F, Dupont A, Bélanger A, Lacourcière Y, Raynaud JP, Husson JM, Gareau J, Fazekas AT, Sandow J, Monfette G, Girard JG, Emond J & Houle JG 1983 New approach in the treatment of prostate cancer: complete instead of only partial withdrawal of androgens. Prostate 4 579-594.
71. Labrie F, Dupont A, Bélanger A, Emond J & Monfette G 1984a Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proceedings of the National Academy of Sciences of the USA 81 3861-3863.
72. Labrie F, Dupont A, Bélanger A, Labrie C, Lacourcière Y, Raynaud JP, Husson JM, Emond J, Houle JG, Girard JG, Monfette G, Paquet JP, Vallières A, Bossé C & Delisle R 1984b Combined antihormonal treatment in prostate cancer: a new approach using an LHRH agonist or castration and an antiandrogen. In Progress in Cancer Research and Therapy, pp 533-547. Eds F Bresciani, RJB King, ME Lippman & JP Raynaud. New York: Raven Press.
73. Labrie F, Dupont A & Bélanger A 1985a Complete androgen blockade for the treatment of prostate cancer. In Important Advances in Oncology, pp 193-217. Eds VT de Vita, S Hellman & SA Rosenberg. Philadelphia: JB Lippincott.
74. Labrie F, Dupont A, Bélanger A, Giguère M, Lacourcière Y, Emond J, Monfette G & Bergeron N 1985b Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. Journal of Steroid Biochemistry 123 833-841.
75. Labrie F, Dupont A, Bélanger A, St-Arnaud R, Giguère M, Lacourcière Y, Emond J & Monfette O 1986 Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrine Reviews 7 67-74.
76. Labrie C, Cusan L, Plante M, Lapointe S & Labrie F 1987a Analysis of the androgenic activity of synthetic 'progestins' currently used for the treatment of prostate cancer. Journal of Steroid Biochemistry 28 379-384.
77. Labrie F, Dupont A, Bélanger A, Giguère M, Borsanyi JP, Lacourcirère Y, Emond J, Monfette G & Lachance R 1987b The importance of combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated as well as previously treated patients with advanced prostate cancer. In Hormonal Modulation of Cancer Peptide Growth Factors and New Antisteroidal Agents, pp 291-300. Eds GM Klijn, R Parideans & JA Foekens. New York: Raven Press.
78. Labrie F, Dupont A, Bélanger A & Lachance R 1987c Flutamide eliminates the risk of disease flare in prostate cancer patients treated with an LHRH agonist. Journal of Urology 138 804-806.
79. Labrie C, Bélanger A & Labrie F 1988 Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 123 1412-1417.
80. Labrie, C, Simard J, Zhao HF, Bélanger A, Pelletier G & Labrie F 1989 Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 124 2745-2754.
81. Labrie C, Simard J, Zhao HF, Pelletier G & Labrie F 1990 Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. Molecular and Cellular Endocrinology 68 169-179.
82. Labrie F, Simard J, Luu-The V, Pelletier G, Belghmi K & Bélanger A 1994 Structure, regulation and role of 3β-hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase and aromatase enzymes in formation of sex steroids in classical and peripheral intracrine tissues. In Hormone, Enzymes and Receptors, pp 451-474. Baillière's Clinical Endocrinology and Metabolism. Eds MC Sheppard & PM Stewart. London: Baillière Tindall.
83. Labrie F, Bélanger A, Simard J, Luu-The V & Labrie C 1995 DHEA and peripheral androgen and estrogen formation: Intracrinology. Annals of the New York Academy of Sciences 774 16-28.
84. Lefebvre FA, Séguin C, Bélanger A, Caron S, Sairam MR, Raynaud JP & Labrie F 1982 Combined long-term treatment with an LHRH agonist and a pure antiandrogen blocks androgenic influence in the rat. Prostate 3 569-578.
85. Lepor H, Ross A & Walsh PC 1982 The influence of hormonal therapy on survival of men with advanced prostatic cancer. Journal of Urology 125 335-340.
86. Limonta P 1992 Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. Journal of Clinical Endocrinology and Metabolism 75 207-212.
87. Limonta P, Moretti RM, Montagnani Marelli M, Dondi D & Motta M 1996 LHRH as a growth-inhibitory factor in prostatic tumor cells: possible mechanism of action. Endocrine-Related Cancer 3 211-216.
88. Lunglmayr G, Girsch E, Mexiner EM, Viehberger G & Bieglmayer C 1988 Effects of long-term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate. Urology Research 16 315-319.
89. Luthy I, Bégin D & Labrie F 1988 Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. Journal of Steroid Biochemistry 31 845-852.
90. MacFarlane DA, Thomas LP & Harrison JH 1960 A survey of total adrenalectomy in cancer of the prostate. American Journal of Surgery 99 562-572.
91. Marchetti B & Labrie F 1984 Further characterization of the direct inhibitory effect of LHRH agonists at the testicular level in the rat. Journal of Steroid Biochemistry 20 339-342.
92. Marchetti B, Plante M, Poulin R & Labrie F 1988 Castration levels of plasma testosterone have potent stimulatory effects on androgen-sensitive parameters in the rat prostate. Journal of Steroid Biochemistry 31 411-419.
93. Markland FS, Chopp RT, Cosgrove MD & Howard EB 1978 Characterization of steroid hormone receptors in the Dunning R-3327 rat prostatic adenocarcinoma. Cancer Research 38 2818-2826.
94. Matsuo H, Baba Y, Nair RMG, Arimura A & Schally AV 1971 Structure of the porcine LH- and FSH-releasing hormone. The proposed amino acid sequence. Biochemical and Biophysical Research Communications 43 1334-1339.
95. Mettlin C, Natarajan N & Murphy GP 1982 Recent patterns of care of prostatic cancer patients in the United States: results from the surveys of the American College of Surgeons Commission on Cancer. International Advances in Surgical Oncology 5 277-321.
96. Moghissi E, Ablan F & Horton R 1984 Origin of plasma androstanediol glucuronide in men. Journal of Clinical Endocrinology and Metabolism 59 417-421.
97. Moguilewsky M, Fiet J, Tournemine C & Raynaud JP 1987 Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer. Journal of Steroid Biochemistry 24 139-146.
98. Monahan MW, Amoss MA, Anderson HA & Vale W 1973 Synthetic analogs of the hypothalamic luteinizing hormone-releasing factor with increased agonist or antagonist properties. Biochemistry 12 4616-4620.
99. Morales PA, Brendler H & Hotchkiss RS 1955 The role of the adrenal cortex in prostatic cancer. Journal of Urology 73 399-409.
100. Mowszowicz I, Bieber DE, Chung KW, Bullock L & Bardin CW 1974 Synandrogenic and antiandrogenic effect of progestins: comparison with non-progestational antiandrogens. Endocrinology 95 1589-1599.
101. Murphy GP & Slack NH 1980 Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate 1 375-382.
102. Murphy GP, Beckley S, Brady MF, Chu M, Dekernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, Loening SA, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino FT, Schlegel JU, Schmidt JD, Scott WW, Slack NH & Soloway M 1983 Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51 1264-1272.
103. Neri, R, Monahan MD, Meyer JG, Afonso BA & Tabachnick IA 1967 Biological studies of an antiandrogen (SH-714). European Journal of Pharmacology 1 438-444.
104. Nesbit RM & Baum WC 1950 Endocrine control of prostatic carcinoma: Clinical and statistical survey of 1818 cases. Journal of the American Medical Association 143 1317-1320.
105. 6,1,2α-methylen-17α-hydroxyprogesteronacetat. In Schilddrüsenhormon und Körperperipherie, 10. Symposium der Deutschen Gesellschaft für Endokrinologie, Wien, 1963, pp 301-304. Ed E Klein. Berlin: Springer-Verlag.
106. Neumann F & Jacobi GH 1982 Antiandrogens in tumor therapy. Clinical Oncology 1 41-65.
107. Neumann F, Graf KJ, Hason SH, Schenche B & Steinbeck H 1977 Central actions of antiandrogens. In Androgens and Antiandrogens, pp 163-171. Eds L Martini & M Motta. New York: Raven Press.
108. Nieschlag E, Akhtar FB, Schürmeyer T & Weinbauer G 1984 LHRH agonists and antagonists for male fertility control: experiments in monkeys and men. In Proceedings of the International Symposium on LHRH and its Analogues: Basic and Clinical Aspects, pp 277-286. Eds F Labrie, A Bélanger & A Dupont. New York: Excerpta Medica.
109. Paisey RB, Kadow C, Bolton C, Hartog M & Gingell JC 1986 Effects of cyproterone acetate and a long acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate. Journal of the Royal Society of Medicine 79 210-211.
110. Parker SL, Tong T, Bolden S & Wingo PA 1996 Cancer statistics 1996. CA Cancer Journal for Clinicians 65 5-27.
111. Peeling WB 1989 Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 33 45-52.
112. Pelletier, G, Labrie C, Simard J, Duval M, Martinoli MG, Zhao HF & Labrie F 1988 Effect of sex steroids on regulation of the levels of C1 peptide of rat prostatic steroid-binding protein mRNA evaluated by in-situ hybridization. Journal of Molecular Endocrinology 1 213-223.
113. Pescatore D, Giberti C, Martorana G, Natta G & Giuliani L 1980 The effect of cyproterone acetate and orchiectomy on metastases from prostatic cancer. European Urology 6 149-153.
114. Plante M, Lapointe S & Labrie F 1988 Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. Journal of Steroid Biochemistry 31 61-64.
115. Poyet P & Labrie F 1985 Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Molecular and Cellular Endocrinology 42 283-288.
116. Rabe T, Feldmann K, Grunwald K & Runnebaum B 1994 Liver tumours in women on oral contraceptives. Lancet 334 1568-1569.
117. Raynaud JP, Bonne C, Bouton MM, Lagacé L & Labrie F 1979 Action of a non-steroidal antiandrogen, RU-23908, in peripheral and central tissues. Journal of Steroid Biochemistry 11 93-99.
118. Resko J, Bélanger A & Labrie F 1982 Effects of chronic treatment with a potent LHRH agonist on serum LH and steroid levels in the male rhesus monkey. Biology of Reproduction 26 378-384.
119. Resnick MI & Gray hack JT 1975 Treatment of stage IV carcinoma of the prostate. Urology Clinics of North America 2 141-161.
120. 9-NEt]-LRF. Life Sciences 25 1065-1074.
121. Rivier J, Ling N, Monahan M, Rivier C, Brown M & Vale W 1975 Luteinizing hormone-releasing factor and somatostatin analogs. In Peptides: Chemistry, Structure and Biology. Proceedings of the Fourth American Peptide Symposium, pp 863-870. Eds R Walter & J Meienhofer. Ann Arbor: Ann Arbor Science.
122. 9-NEt]luteinizing hormone-releasing factor on reproductive processes in the female rat. Endocrinology 103 2299-2305.
123. 9-NEt]luteinizing hormone-releasing factor on reproductive processes in the male rat. Endocrinology 105 1191-1201.
124. Rivier CL, Rivier JEF & Vale WW Jr 1980 Peptide which inhibits gonadal function. US Patent No. 4,218,439.
125. Robinson MR 1988 EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Progress in Clinical and Biological Research 260 101-110.
126. Robinson MR & Thomas BS 1971 Effect of hormone therapy on plasma testosterone levels in prostatic cancer. British Medical Journal 4 391-394.
127. Sandow J, Von Rechenberg W, Jerzabek G & Stoll W 1978 Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertility and Sterility 30 205-211.
128. Sanford EJ, Paulson DF, Rohner TJ, Drago JR, Santen RJ & Bardin CW 1977 Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. Journal of Urology 118 1019-1021.
129. Schally AV, Kastin AJ & Coy DH 1976 LH-releasing hormone and its analogues: recent basic and clinical investigations. International Journal of Fertility 21 1-30.
130. Schally AV, Redding TW & Comaru-Schally AM 1984 Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treatment Reports 68 281-289.
131. Schulze T & Isaacs JT 1986 Biology and therapy of prostatic cancer. Cancer Surveys 5 487-503.
132. Schwarztein L 1976 Diagnostic and therapeutic use of LHRH in the infertility in man. In Hypothalamus and Endocrine Functions, pp 73-91. Eds F Labrie, J Meites & G Pelletier. New York: Plenum Press.
133. Sciarra F, Toscano V, Concolino G & DiSilverio F 1990 Antiandrogens: clinical applications. Journal of Steroid Biochemistry and Molecular Biology 37 349-362.
134. Scott WW 1983 Historical overview of the treatment of prostatic cancer. Prostate 4 435-440.
135. Seed M, Godsland IF, Wynn V & Jacob HS 1984 The effects of cyproterone acetate and ethinyl estradiol on carbohydrate metabolism. Clinical Endocrinology 21 689-699.
136. Séguin C, Cusan L, Bélanger A, Kelly PA, Labrie F & Raynaud JP 1981 Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat. Molecular and Cellular Endocrinology 21 37-41.
137. Sharpe RM & Fraser HM 1980 Leydig cell receptors for luteinizing hormone-releasing hormone and its agonists and their modulation by administration or deprivation of the releasing hormone. Biochemical and Biophysical Research Communications 95 256-262.
138. Sogani PC, Ray B & Whitmore WF 1975 Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment. Urology 6 164-166.
139. St-Arnaud R, Lachance R, Kelly SJ, Bélanger A, Dupont A & Labrie F 1986 Loss of luteinizing hormone (LH) bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen. Clinical Endocrinology 24 21-30.
140. Staubitz WJ, Oberkircher OJ & Lent MH 1954 Clinical results of the treatment of prostatic carcinoma over a ten-year period. Journal of Urology 72 939-945.
141. van Steenbrugge GJ, Romijn JC, de Jong FH & Schröder FH 1984 Unresponsiveness of the reproductive organs of the male mouse to treatment with a potent luteinizing hormone-releasing hormone agonist (ICI-118,630). Urology Research 12 175-178.
142. Stoliar B & Albert DJ 1974 SCH13521 in the treatment of advanced carcinoma of the prostate. Journal of Urology 111 803-807.
143. Sufrin G & Coffey DS 1976 Flutamide mechanism of action of a new steroidal antiandrogen. Investigative Urology 13 429-435.
144. 10]LHRH ethylamide in male rats. Fertility and Sterility 30 600-603.
145. Thompson IM, Zeidman FJ & Rodriguez FR 1990 Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. Journal of Urology 144 1479-1480.
146. Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas ATA, Comaru-Schally AM & Schally AV 1982 Tumor growth inhibition in patients with prostatic carcinoma treated with LHRH agonists. Proceedings of the National Academy of Sciences of the USA 79 1558-1662.
147. Tveter KJ, Otnes B & Hannestad R 1978 Treatment of prostatic carcinoma with cyproterone acetate. Scandanavian Journal of Urology and Nephrology 12 115-118.
148. VACURG 1967 Treatment and survival of patients with cancer of the prostate. Surgery Gynecology and Obstetrics 124 1011-1017.
149. 6-gonadotropin-releasing hormone polyethylamide on the hypothalamic-pituitary-testicular axis in patients with prostatic cancer. Journal of Clinical Investigation 71 1842-1855.
150. Wass JAH, Besser GM, Gomez-Pan A, Scanlon MF, Hall R, Kastin AJ, Coy DH & Serially AV 1979 Comparison of long-acting analogues of luteinizing hormone releasing hormone in man. Clinical Endocrinology 10 419-430.
151. Waxman JH, Wass JAH, Hendry WF, Whitfield HN, Besser GM, Malpas JS & Oliver RT 1983 Treatment with gonadotropin-releasing hormone analogue in advanced prostatic cancer. British Medical Journal 286 1309-1312.
152. Waxman J, Man A, Hendry WF, Whitfield HN, Besser GM, Tiptaft RC, Paris AM & Olivier RT 1985 Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. British Medical Journal 291 1387-1388.
153. Wickings EJ, Zaidi P, Brabant G & Nieschlag E 1981 Stimulation of pituitary and testicular functions with LH-RH agonist or pulsatile LH-RH treatment in the rhesus monkey during the non-breeding season. Journal of Reproduction and Fertility 63 129-136.
154. 6,LHRH,1-9EA10 on gonadotropin and gonadal steroid secretion in men after intraveneous and intranasal application. Acta Endocrinologica (Suppl) 212 57.